We are live on ! Find out more
DSGN icon

Design Therapeutics
DSGN

100 hedge funds and large institutions have $172M invested in Design Therapeutics in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

60% more capital invested

Capital invested by funds: $108M → $172M (+$64.8M)

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

5% more funds holding

Funds holding: 95 → 100 (+5)

0.24% less ownership

Funds ownership: 56.81% → 56.57% (-0.24%)

12% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 34

90% less call options, than puts

Call options by funds: $18K | Put options by funds: $175K

Holders
100
Holders Change
+5
Holders Change %
+5.26%
% of All Funds
1.44%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
14
Increased
30
Reduced
34
Closed
9
Calls
$18K
Puts
$175K
Net Calls
-$157K
Net Calls Change
-$87K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.52M
2
FLSM
Frazier Life Sciences Management
California
+$3.28M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.87M
4
Citadel Advisors
Citadel Advisors
Florida
+$1.27M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$457K

Top Sellers

1
LGM
Logos Global Management
California
-$3.83M
2
Millennium Management
Millennium Management
New York
-$1.9M
3
Goldman Sachs
Goldman Sachs
New York
-$1.54M
4
BCM
BML Capital Management
Indiana
-$1.41M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$922K
Name Holding Trade Value Shares
Change 		Change in
Stake
SOCM
1
SR One Capital Management
Pennsylvania
$35.1M – – –
LGM
2
Logos Global Management
California
$22.7M -$3.83M -814,874 -16%
BlackRock
3
BlackRock
New York
$12.7M +$253K +53,849 +2%
FLSM
4
Frazier Life Sciences Management
California
$10.2M +$3.28M +697,368 +58%
BBA
5
Baker Bros. Advisors
New York
$9.38M +$228K +48,431 +3%
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$8.61M +$2.87M +609,939 +62%
TCM
7
Tang Capital Management
California
$7.97M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$7.5M +$457K +97,236 +7%
AC
9
Almitas Capital
California
$7.12M +$331K +70,419 +6%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$4.46M +$3.52M +747,649 +923%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$4.08M +$238K +50,579 +7%
State Street
12
State Street
Massachusetts
$3.72M -$21.6K -4,597 -0.7%
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$3.14M +$221K +47,074 +9%
Acadian Asset Management
14
Acadian Asset Management
Massachusetts
$3.13M – – –
Citadel Advisors
15
Citadel Advisors
Florida
$3.1M +$1.27M +270,920 +89%
Morgan Stanley
16
Morgan Stanley
New York
$2.31M +$185K +39,361 +10%
Assenagon Asset Management
17
Assenagon Asset Management
Luxembourg
$1.86M -$7.53K -1,602 -0.5%
PGCM
18
Prescott Group Capital Management
Oklahoma
$1.85M – – –
Northern Trust
19
Northern Trust
Illinois
$1.81M -$2.69K -571 -0.2%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$1.64M -$448K -95,200 -24%
Two Sigma Investments
21
Two Sigma Investments
New York
$1.64M -$463K -98,471 -24%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$1.51M -$922K -195,987 -41%
Goldman Sachs
23
Goldman Sachs
New York
$1.48M -$1.54M -328,173 -54%
Renaissance Technologies
24
Renaissance Technologies
New York
$1.47M -$518K -110,075 -29%
Charles Schwab
25
Charles Schwab
California
$1.38M +$364K +77,472 +43%
1
2 3 4 5

DSGN Hedge Fund Activity: Q3 2024 in Review

100 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q3 2024, worth a combined $172M — up 60% from $108M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new DSGN positions and 9 closed out — a net gain of 5 holders — while 30 added to existing stakes and 34 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $3.52M. The largest seller was Logos Global Management, cutting an estimated $3.83M.

  • 100 institutional investors held Design Therapeutics (DSGN) as of Q3 2024, up from 95 in Q2 2024.
  • Funds reported $172M of Design Therapeutics stock for Q3 2024, up 60% quarter-over-quarter.
  • 14 funds opened new Design Therapeutics positions in Q3 2024 and 9 closed out, a net change of +5 holders.
  • The largest Design Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $3.52M added.
  • The largest Design Therapeutics seller in Q3 2024 was Logos Global Management, an estimated $3.83M sold.

Based on aggregated 13F filings for Q3 2024.